Goldman Sachs initiated coverage of Exelixis (EXEL) with a Buy rating and $47 price target The recent share pullback creates an attractive entry point, the analyst tells investors in a research note. The firm expects continued Cabometyx commercial execution and believes the pending zanzalintinib data will solidify Exelixis’ longer term outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis assumed with an Equal Weight at Barclays
- Exelixis initiated with an Equal Weight at Barclays
- Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
- Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
- Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating